622 related articles for article (PubMed ID: 30927306)
21. Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
Dal Maso A; Lorenzi M; Roca E; Pilotto S; Macerelli M; Polo V; Cecere FL; Del Conte A; Nardo G; Buoro V; Scattolin D; Monteverdi S; Urso L; Zulato E; Frega S; Bonanno L; Indraccolo S; Calabrese F; Conte P; Pasello G
Clin Lung Cancer; 2020 Jan; 21(1):1-14.e3. PubMed ID: 31601525
[TBL] [Abstract][Full Text] [Related]
22. Correlation Analysis between T790M Status and Clinical Characteristics of Patients with EGFR-sensitive Mutation Advanced NSCLC who Progressed after the First Generation and First-line EGFR-TKIs Administration: A Real-world Exploratory Study.
Zhen Y; Xu YB; Deng RY; Li M; Ma MT; Zhou ZG; Meng QJ; Gong YN; Zhao LY; Liu YB
Comb Chem High Throughput Screen; 2024; 27(6):845-853. PubMed ID: 37282652
[TBL] [Abstract][Full Text] [Related]
23. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC
Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652
[TBL] [Abstract][Full Text] [Related]
24. First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study.
Kudo K; Nishii K; Makimoto G; Ishikawa N; Tsubata Y; Kodani M; Fujimoto N; Yamasaki M; Kubota T; Takigawa N; Fujitaka K; Kanaji N; Shibayama T; Itano J; Ando C; Hotta K; Kiura K
J Cancer Res Clin Oncol; 2022 Aug; 148(8):1869-1877. PubMed ID: 35386002
[TBL] [Abstract][Full Text] [Related]
25. When compared to plasma-based detection, osimertinib-treated non-small cell lung cancer (NSCLC) with tissue rebiopsy-confirmed acquired T790M mutation is associated with better survival.
Kwok WC; Ho JCM; Lam DCL; Lui MMS; Ip MSM; Tam TCC
Asia Pac J Clin Oncol; 2021 Apr; 17(2):e35-e39. PubMed ID: 31802642
[TBL] [Abstract][Full Text] [Related]
26. Sequential treatment in advanced non-small cell lung cancer harboring EGFR mutations.
Hsu PC; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Wu CE
Ther Adv Respir Dis; 2022; 16():17534666221132731. PubMed ID: 36305280
[TBL] [Abstract][Full Text] [Related]
27. Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
Oya Y; Yoshida T; Asada K; Oguri T; Inui N; Morikawa S; Ito K; Kimura T; Kunii E; Matsui T; Kubo A; Kato T; Abe T; Tsuda T; Hida T
BMC Cancer; 2021 Jan; 21(1):57. PubMed ID: 33435905
[TBL] [Abstract][Full Text] [Related]
28. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
29. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
Ikushima H; Sakatani T; Usui K
Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
[TBL] [Abstract][Full Text] [Related]
30. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
Zhang YC; Chen ZH; Zhang XC; Xu CR; Yan HH; Xie Z; Chuai SK; Ye JY; Han-Zhang H; Zhang Z; Bai XY; Su J; Gan B; Yang JJ; Li WF; Tang W; Luo FR; Xu X; Wu YL; Zhou Q
EBioMedicine; 2019 May; 43():180-187. PubMed ID: 31027916
[TBL] [Abstract][Full Text] [Related]
31. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
32. Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
Lee J; Kim HS; Lee B; Kim HK; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Cancer; 2020 Jun; 126(11):2704-2712. PubMed ID: 32154925
[TBL] [Abstract][Full Text] [Related]
33. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
34. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Hida T; Yatabe Y
Clin Lung Cancer; 2017 Nov; 18(6):698-705.e2. PubMed ID: 28596108
[TBL] [Abstract][Full Text] [Related]
35. Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI.
Chiang CL; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH
Target Oncol; 2020 Aug; 15(4):503-512. PubMed ID: 32696212
[TBL] [Abstract][Full Text] [Related]
36. Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice.
Ito K; Suzuki Y; Saiki H; Sakaguchi T; Hayashi K; Nishii Y; Watanabe F; Hataji O
Clin Lung Cancer; 2018 Mar; 19(2):181-190. PubMed ID: 29174086
[TBL] [Abstract][Full Text] [Related]
37. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
38. Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.
Koo HJ; Kim MY; Park S; Lee HN; Kim HJ; Lee JC; Kim SW; Lee DH; Choi CM
Radiology; 2018 Oct; 289(1):227-237. PubMed ID: 30015588
[TBL] [Abstract][Full Text] [Related]
39. Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients: Potential Clinical Impact on Subsequent third-generation TKI Treatment.
Iacono D; Osman GA; Migliorino MR; Grillo L; Remotti D; Nunnari J; Ricciardi S; Rossi A; Mancuso A; Graziano P; Di Lorenzo A; Bronzini M; Signora M; Leone A
Am J Clin Oncol; 2019 Nov; 42(11):845-850. PubMed ID: 31644442
[TBL] [Abstract][Full Text] [Related]
40. T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring
Kogure Y; Shigematsu F; Oki M; Saka H
In Vivo; 2018; 32(5):1199-1204. PubMed ID: 30150444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]